Clearpoint Neuro Inc
NASDAQ:CLPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (23), the stock would be worth $-18.98 (284% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -12.6 | $10.34 |
0%
|
| Industry Average | 23 | $-18.98 |
-284%
|
| Country Average | 23.2 | $-19.13 |
-285%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Clearpoint Neuro Inc
NASDAQ:CLPT
|
303.7m USD | -12.6 | -11.9 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 62.3 | 56.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 21.6 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 30.7 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 22.4 | 22.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 25.7 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 32.6 | 43 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 42.6 | 41.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 20.5 | 18.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 21.9 | 23.5 | |
| US |
|
Resmed Inc
NYSE:RMD
|
30.9B USD | 16.8 | 20.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.4 |
| Median | 23.2 |
| 70th Percentile | 35.1 |
| Max | 3 178 983.5 |
Other Multiples
Clearpoint Neuro Inc
Glance View
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The company is headquartered in Solana Beach, California and currently employs 80 full-time employees. The company went IPO on 2019-07-03. The Company’s product platforms include SmartFlow Cannula and ClearPoint Navigation System Software. The SmartFlow Cannula is being utilized in approved combination product clinical and preclinical studies by pharmaceutical companies and academic research customers for various research and clinical trials in connection with delivery of therapeutic agents. The ClearPoint Navigation System Software is a software for surgical planning, navigation to target, and device delivery. The Company’s software and MRI-compatible workstation coordinate with the scanner to effectively utilize intraprocedural MR images. This provides real-time navigational instruction for the neurosurgeon to reach the desired anatomical target with a high degree of precision.
